Jefferies analyst Andrew Tsai assumed coverage of Supernus Pharmaceuticals with a Buy rating and price target of $45, up from $44. Key opinion leader discussions suggest the recent launch of oral Qelbree, a non-stimulant for attention-deficit/hyperactivity disorder, could reach $750M in peak sales, above the current consensus estimate of $550M and up from a current $75M run rate, Tsai tells investors in a research note. The analyst says 2023 will mark a tough year-over-year comp due to the loss of Trokendi XR, but says this dynamic is widely understood. HE is confident Qelbree and Supernus’s other marketed products will stabilize and grow revenues thereafter.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SUPN:
- Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
- Supernus to Present at Two November Healthcare Conferences
- Supernus reports Q3 EPS 3c, may not compare to consensus 36c
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue